Agile Therapeutics is a technology company.
Agile Therapeutics has raised $85.0M across 2 funding rounds.
Agile Therapeutics has raised $85.0M in total across 2 funding rounds.
Agile Therapeutics has raised $85.0M in total across 2 funding rounds.
Agile Therapeutics's investors include Aisling Capital, Morgenthaler Ventures, Novo Ventures.
Agile Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing prescription contraceptive products for women, particularly innovative options that avoid daily pills. Based in Princeton, New Jersey, it targets women's healthcare needs by creating transdermal patch-based solutions like those involving ethinylestradiol/levonorgestrel for contraception, which has reached approved status.[1][2][4][5][6] The company serves women seeking reliable, non-oral birth control, addressing challenges like adherence to daily regimens, with a pipeline including three drug delivery devices and small molecule drugs.[3][4][5] Growth has been supported by state programs in New Jersey, and it recently completed an acquisition, signaling ongoing momentum despite stock market challenges as a public entity (AGRX).[1][2][5]
Agile Therapeutics emerged in the women's health space with a focus on novel contraceptive delivery methods, though exact founding details are not specified in available sources. The company has built traction through clinical development, with key products like ethinylestradiol/levonorgestrel (targeting ER and PR receptors) achieving approval—first in the United States on May 10, 1982, for related indications, and Agile's efforts starting trials as early as 2012 and 2014.[4] Pivotal moments include leveraging New Jersey state programs for sustained growth and completing an acquisition, which underscores its evolution from R&D-focused biotech to a commercializing entity with 9 clinical trials, 114 news mentions, and patent activity.[1][4][5]
Agile Therapeutics rides the trend toward patient-centric drug delivery innovations in women's health, where non-oral contraceptives address global adherence gaps—pills fail up to 9% due to missed doses. Timing aligns with rising demand for convenient, tech-enabled pharma solutions like patches, amid market forces favoring specialty biotechs post-acquisition for scale.[5] It influences the ecosystem by pioneering drug-device hybrids, contributing to broader contraceptive access and R&D in hormone therapies, while New Jersey's incentives bolster U.S. biotech hubs.[1][4]
Post-acquisition, Agile is positioned to expand commercialization of its patch contraceptives and pipeline, potentially capturing more market share in non-daily options amid telemedicine and personalized medicine trends. Evolving regulatory support and women's health investments could amplify growth, though execution on pipeline approvals will be key. This specialty pharma innovator exemplifies how targeted delivery tech transforms everyday health challenges, tying back to its core mission of empowering women beyond the pill.
Agile Therapeutics has raised $85.0M across 2 funding rounds. Most recently, it raised $40.0M Series C in July 2012.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2012 | $40.0M Series C | Aisling Capital, Morgenthaler Ventures, Novo Ventures | |
| Jun 1, 2010 | $45.0M Series B | Novo Ventures |